Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade <i>IDH</i>-mutant gliomas

Yu Yao(Qinghai University), Nancy Ann Oberheim Bush(University of California, San Francisco), Joanna J. Phillips(University of California, San Francisco), Bruce H. Wainer(University of Chicago), Annette M. Molinaro(University of California, San Francisco), Javier Villanueva‐Meyer(Baylor College of Medicine), Jennifer Clarke(Cornell University), Stephanie Hilz(University of California, San Francisco), Michael Wahl(Regional Cancer Center), Anny Shai(University of California, San Francisco), Matthew Grimmer(Sequenom (United States)), Jennie Taylor(University of California, San Francisco), Daphne A. Haas‐Kogan(Brigham and Women's Hospital), David A. Solomon(University of California, San Francisco), J Costello(University of California, San Francisco), Nicholas Butowski(University of California, San Francisco), Michael McDermott(University of California, San Francisco), Serah Choi(University of Pittsburgh Medical Center), Chibo Hong(Universidad Católica de Santa Fe), Tali Mazor(Dana-Farber Cancer Institute), Susan M. Chang(University of San Francisco), Mitchel S. Berger(University of California, San Francisco)
Neuro-Oncology
March 31, 2021
Cited by 127


Related Papers